Alexion to Acquire Syntimmune for antibody therapeutics targeting the neonatal Fc receptor (FcRn)

 Alexion to Acquire Syntimmune for antibody therapeutics targeting the neonatal Fc receptor (FcRn)

Alexion to Acquire Syntimmune for antibody therapeutics targeting the neonatal Fc receptor (FcRn)

Shots:

  • Alexion to acquire Syntimmune for $1.2B in cash, including an upfront payment of $400M, with additional milestone payments of up to $800M. The transaction is expected to close in Q4’18
  • Alexion to get the SYNT001 through this acquisition, which a humanized monoclonal antibody, which inhibits the binding of FcRn with Immunoglobulin G (IgG) and IgG immune complexes. It is being developed for the treatment of IgG-mediated rare diseases
  • SYNT001 is currently tested in P-Ib/IIa studies for warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV) or pemphigus foliaceus (PF) and has been validated in rapid IgG reduction

Click here to read full press release/ article | Ref: Alexion | Image: Syntimmune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post